Streetbeat News

MIRA

MIRA Pharmaceuticals, Inc.

https://mirapharmaceuticals.com

Industry

Drug Manufacturers - General

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.

Open

1.28

Mkt cap

21M

Volume

357K

High

1.33

P/E Ratio

-2.40

52-wk high

5.01

Low

1.23

Div yield

N/A

52-wk low

0.51

In Friday's after-market session, several healthcare stocks showed notable movements. Talphera's shares surged by 15.6% following its Q4 earnings report. Other gainers included Genelux, Estrella Immunopharma, Inspire Veterinary, NRX Pharmaceuticals, and Fortrea Holdings with increases ranging from 5.02% to 10.06%. Conversely, Atara Biotherapeutics led the losers, dropping by 9.4%, followed by declines in ProKidney, Mira Pharmaceuticals, Yield10 Bioscience, GeneDx Hldgs, and Envoy Medical.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 9:31 pm

Mira Pharmaceuticals Inc (NASDAQ:MIRA) announced the discovery of a new molecule, MIRA-55, initially mistaken for their drug candidate MIRA1a. MIRA-55, showing enhanced potency for treating anxiety and cognitive decline, has led to a provisional patent application. The company's stock surged 39.01% to $1.32 following the news.

Portfolio Pulse from Vandana Singh

March 08, 2024 | 6:00 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. Psyence Biomedical led the gainers with a 137.8% increase, while Amylyx Pharma saw the largest decline among the losers, dropping 81.5%. Other notable movers included Ainos, Mira Pharmaceuticals, and Joint, with substantial gains, and Immuron, Jin Medical International, and eFFECTOR Therapeutics among the losers.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 5:31 pm

Porch Group, Inc. (NASDAQ:PRCH) shares surged 20.5% in pre-market trading after reporting Q4 financial results that exceeded expectations and providing optimistic FY24 guidance. Other stocks also showed significant movement in pre-market trading, with notable gainers including Ainos, Inc. (AIMD), MIRA Pharmaceuticals, Inc. (MIRA), and CERo Therapeutics Holdings, Inc. (CERO), among others. Conversely, several companies experienced declines, such as AerSale Corporation (ASLE), Brera Holdings PLC (BREA), and BigBear.ai Holdings, Inc. (BBAI), following disappointing financial results or other company-specific news.

Portfolio Pulse from Avi Kapoor

March 08, 2024 | 1:23 pm

In Friday's pre-market session, health care stocks showed significant movement. Ainos, Psyence Biomedical, and Mira Pharmaceuticals were among the top gainers, with Ainos leading at a 144.6% increase. On the downside, Amylyx Pharma experienced a significant drop of 81.5%. Other notable movers include Viracta Therapeutics with a 17.18% increase following their Q4 earnings report, and ALX Oncology Holdings, which fell 10.41% also after their Q4 earnings.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 1:09 pm

In Tuesday's after-market session, several health care stocks showed significant movement. Sharps Technology and DMK Pharmaceuticals led the gainers with over 20% increases in their stock prices, while Exicure and Yield10 Bioscience were among the top losers, experiencing declines of over 6%. Notably, Arrowhead Pharma and Varex Imaging reported their Q1 earnings, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

February 06, 2024 | 9:31 pm

Air Products and Chemicals, Inc. (APD) shares fell by around 15% after reporting Q1 financial results below expectations and lowering FY24 EPS guidance. Other stocks showed significant movements, with notable gainers including Yield10 Bioscience (YTEN) and 4D Molecular Therapeutics (FDMT), and losers like NanoString Technologies (NSTG) and DMK Pharmaceuticals (DMK) due to bankruptcy proceedings.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 5:56 pm

In Monday's intraday session, several healthcare stocks experienced significant movements. Notably, 4D Molecular Therapeutics (FDMT) surged 75.2%, while NanoString Technologies (NSTG) plummeted by 70.9%. Other notable gainers include Yield10 Bioscience (YTEN) and MorphoSys (MOR), with increases of 61.76% and 50.76% respectively. On the losing end, Invitae (NVTA) and DMK Pharmaceuticals (DMK) saw declines of 61.9% and 52.5%.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 5:31 pm

MIRA Pharmaceuticals' shares surged following the announcement of a research collaboration with Pharmaseed to study Ketamir's effects on major depressive disorder and PTSD patients.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 4:35 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.